We should discuss these issues with our patients to help them decide on the kind of matricectomy.
The authors have indicated no significant interest with commercial supporters.”
“Purpose of review
The purpose of this review is to describe the new insights of hepatitis C virus (HCV) infection and renal transplantation.
Recent findings
HCV is its most frequent cause of liver disease after transplantation. In the long run, HCV infection can lead to
cirrhosis, hepatocarcinoma and death in some patients. As interferon is generally contraindicated after transplantation, the best way to treat patients is before transplantation. Long-term patient and graft survival rates are lower in HCV-positive patients than in HCV-negative graft recipients. HCV infection is an IWR-1-endo Stem Cells & Wnt inhibitor independent risk factor for death and graft loss. Mortality is higher, mainly as a result of cardiovascular complications, liver disease and infections but is lower than in HCV-positive patients on the transplant waiting list. New-onset diabetes after transplantation (NODAT), and HCV-related glomerulonephritis, together with chronic https://www.selleckchem.com/products/cl-amidine.html rejection and notably transplant glomerulopathy can contribute to graft failure. Despite this factor, transplantation is the best option for the HCV-positive patient on dialysis. Renal transplantation with kidneys from donors with positive anti-HCV antibodies into HCV RNA-positive recipients seems to be safe in the long term.
Summary
Renal
transplantation is the therapy of choice for dialysis patients with HCV infection.
To improve the results, a careful follow-up in the outpatient clinic for early detection of HCV-related complications is mandatory.”
“Purpose of review
A persistent challenge facing the transplant community is avoiding renal compromise, whether protecting a newly placed kidney allograft or preserving CDK inhibitors in clinical trials native renal function after another organ has been implanted. One of the principal ways to achieve this is by altering the immunosuppressive regimen. We review some of the more important recent studies in this area.
Recent findings
Over the past year, two new immunosuppressive agents have received attention. An immunoselective biologic agent, belatacept, continued to demonstrate a sustained benefit in renal function when compared with a cyclosporine-based regimen. In a phase 2 multicenter study, sotrastaurin, a protein kinase C inhibitor, has shown promise in preserving renal graft function but lacks potency as an immunosuppressive agent. A known agent, everolimus, in combination with reduced doses of calcineurin inhibitors or with other agents, continues to be in the forefront as a promising renal-sparing option. Finally, further investigation into mycophenolate mofetil has shown that it has some advantages as a long-term agent when used in monotherapy.
Summary
The new therapies investigated show some promise as potential alternative agents.